| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infertility, Male | 119 | 2026 | 297 | 18.640 |
Why?
|
| Testosterone | 86 | 2025 | 603 | 16.970 |
Why?
|
| Hypogonadism | 52 | 2025 | 322 | 12.270 |
Why?
|
| Hormone Replacement Therapy | 28 | 2025 | 214 | 6.780 |
Why?
|
| Azoospermia | 22 | 2023 | 48 | 6.370 |
Why?
|
| Spermatozoa | 52 | 2026 | 258 | 6.310 |
Why?
|
| Varicocele | 33 | 2020 | 61 | 6.290 |
Why?
|
| Vasovasostomy | 19 | 2018 | 22 | 4.710 |
Why?
|
| Erectile Dysfunction | 28 | 2023 | 196 | 4.490 |
Why?
|
| Shift Work Schedule | 7 | 2025 | 29 | 3.920 |
Why?
|
| Androgens | 16 | 2020 | 272 | 3.730 |
Why?
|
| Spermatogenesis | 30 | 2024 | 171 | 3.370 |
Why?
|
| Male | 353 | 2026 | 65264 | 3.360 |
Why?
|
| Sperm Count | 39 | 2024 | 92 | 3.150 |
Why?
|
| Microsurgery | 11 | 2019 | 64 | 2.960 |
Why?
|
| Chorionic Gonadotropin | 11 | 2024 | 80 | 2.940 |
Why?
|
| Testis | 44 | 2023 | 413 | 2.920 |
Why?
|
| Sperm Injections, Intracytoplasmic | 16 | 2026 | 50 | 2.920 |
Why?
|
| Vasectomy | 11 | 2018 | 16 | 2.910 |
Why?
|
| Oligospermia | 41 | 2016 | 65 | 2.770 |
Why?
|
| Penile Induration | 9 | 2024 | 38 | 2.730 |
Why?
|
| Fertility | 18 | 2026 | 266 | 2.690 |
Why?
|
| Sperm Motility | 30 | 2026 | 112 | 2.660 |
Why?
|
| Semen Analysis | 15 | 2026 | 36 | 2.570 |
Why?
|
| Reproductive Techniques, Assisted | 10 | 2024 | 80 | 2.540 |
Why?
|
| Urology | 7 | 2025 | 84 | 2.450 |
Why?
|
| Fertilization in Vitro | 26 | 2026 | 160 | 2.440 |
Why?
|
| Humans | 362 | 2026 | 131671 | 2.390 |
Why?
|
| Penis | 13 | 2022 | 97 | 2.350 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 3 | 2025 | 24 | 2.200 |
Why?
|
| Anal Canal | 6 | 2013 | 86 | 2.130 |
Why?
|
| Estradiol | 12 | 2017 | 481 | 2.010 |
Why?
|
| Semen | 23 | 2023 | 85 | 1.970 |
Why?
|
| Prostatic Neoplasms | 18 | 2025 | 1418 | 1.920 |
Why?
|
| Follicle Stimulating Hormone | 28 | 2024 | 188 | 1.890 |
Why?
|
| Pregnancy Rate | 5 | 2026 | 40 | 1.850 |
Why?
|
| Vas Deferens | 12 | 2021 | 23 | 1.840 |
Why?
|
| Paternal Age | 6 | 2024 | 16 | 1.740 |
Why?
|
| Adult | 129 | 2026 | 31717 | 1.720 |
Why?
|
| Lower Urinary Tract Symptoms | 5 | 2019 | 40 | 1.700 |
Why?
|
| Patient Satisfaction | 6 | 2024 | 460 | 1.630 |
Why?
|
| Libido | 7 | 2019 | 34 | 1.620 |
Why?
|
| Anabolic Agents | 6 | 2014 | 15 | 1.570 |
Why?
|
| Genitalia, Male | 5 | 2014 | 35 | 1.560 |
Why?
|
| Fathers | 5 | 2024 | 71 | 1.480 |
Why?
|
| Sperm Retrieval | 7 | 2023 | 12 | 1.440 |
Why?
|
| Sexual Dysfunction, Physiological | 9 | 2018 | 85 | 1.390 |
Why?
|
| Urologic Surgical Procedures, Male | 7 | 2019 | 34 | 1.320 |
Why?
|
| Retrospective Studies | 55 | 2025 | 17667 | 1.290 |
Why?
|
| Penile Erection | 10 | 2023 | 82 | 1.290 |
Why?
|
| Middle Aged | 79 | 2025 | 28886 | 1.260 |
Why?
|
| Reproduction | 4 | 2016 | 215 | 1.240 |
Why?
|
| Scrotum | 7 | 2013 | 30 | 1.240 |
Why?
|
| Microbial Collagenase | 6 | 2024 | 10 | 1.220 |
Why?
|
| Work Schedule Tolerance | 2 | 2020 | 41 | 1.200 |
Why?
|
| Organ Transplantation | 3 | 2020 | 172 | 1.170 |
Why?
|
| Male Urogenital Diseases | 3 | 2021 | 15 | 1.160 |
Why?
|
| Sexual Behavior | 5 | 2016 | 245 | 1.100 |
Why?
|
| Ejaculatory Ducts | 7 | 2019 | 10 | 1.100 |
Why?
|
| Semen Preservation | 6 | 2025 | 16 | 1.100 |
Why?
|
| Penile Prosthesis | 5 | 2022 | 40 | 1.090 |
Why?
|
| Occupational Diseases | 3 | 2019 | 78 | 1.090 |
Why?
|
| Infertility | 5 | 2024 | 79 | 1.080 |
Why?
|
| Fertility Agents, Male | 3 | 2016 | 6 | 1.030 |
Why?
|
| Fertility Preservation | 4 | 2025 | 62 | 1.020 |
Why?
|
| Quality of Life | 9 | 2022 | 2117 | 1.020 |
Why?
|
| Andrology | 2 | 2016 | 3 | 0.990 |
Why?
|
| Eunuchism | 2 | 2016 | 7 | 0.950 |
Why?
|
| Abortion, Habitual | 2 | 2016 | 17 | 0.930 |
Why?
|
| Cryopreservation | 9 | 2025 | 79 | 0.930 |
Why?
|
| Fees, Medical | 1 | 2025 | 7 | 0.920 |
Why?
|
| Luteinizing Hormone | 17 | 2018 | 134 | 0.910 |
Why?
|
| Surveys and Questionnaires | 18 | 2024 | 4047 | 0.910 |
Why?
|
| Neoplasms | 12 | 2025 | 2969 | 0.900 |
Why?
|
| Aneuploidy | 3 | 2016 | 141 | 0.900 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2025 | 36 | 0.890 |
Why?
|
| Cryptorchidism | 9 | 2014 | 38 | 0.890 |
Why?
|
| Urologic Surgical Procedures | 1 | 2025 | 62 | 0.880 |
Why?
|
| Dihydrotestosterone | 3 | 2015 | 72 | 0.870 |
Why?
|
| Sleep | 3 | 2016 | 373 | 0.870 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2025 | 68 | 0.850 |
Why?
|
| Gynecology | 1 | 2025 | 129 | 0.820 |
Why?
|
| Treatment Outcome | 37 | 2024 | 12984 | 0.810 |
Why?
|
| Men's Health | 3 | 2021 | 22 | 0.800 |
Why?
|
| Posthumous Conception | 2 | 2013 | 4 | 0.800 |
Why?
|
| Pregnancy | 30 | 2026 | 7572 | 0.790 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 775 | 0.770 |
Why?
|
| Prostatectomy | 10 | 2013 | 313 | 0.750 |
Why?
|
| Epididymis | 9 | 2013 | 66 | 0.730 |
Why?
|
| Reproductive Health | 3 | 2021 | 48 | 0.730 |
Why?
|
| Office Visits | 3 | 2015 | 81 | 0.710 |
Why?
|
| Medicare | 1 | 2025 | 437 | 0.710 |
Why?
|
| Cough | 1 | 2022 | 99 | 0.700 |
Why?
|
| Congenital Abnormalities | 3 | 2019 | 322 | 0.690 |
Why?
|
| Ultrasonography, Doppler, Duplex | 2 | 2018 | 34 | 0.670 |
Why?
|
| Orchiectomy | 3 | 2019 | 52 | 0.670 |
Why?
|
| Seasons | 2 | 2013 | 333 | 0.670 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2014 | 48 | 0.670 |
Why?
|
| Thrombosis | 3 | 2015 | 495 | 0.660 |
Why?
|
| Reproductive Medicine | 3 | 2018 | 19 | 0.660 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2016 | 755 | 0.640 |
Why?
|
| Receptors, Androgen | 8 | 2018 | 418 | 0.640 |
Why?
|
| Prostate-Specific Antigen | 7 | 2025 | 236 | 0.640 |
Why?
|
| Vasodilator Agents | 4 | 2014 | 201 | 0.640 |
Why?
|
| DNA Fragmentation | 4 | 2016 | 56 | 0.640 |
Why?
|
| Estrogen Antagonists | 2 | 2020 | 92 | 0.630 |
Why?
|
| Seminal Vesicles | 3 | 2017 | 52 | 0.630 |
Why?
|
| Prostatic Hyperplasia | 3 | 2018 | 119 | 0.620 |
Why?
|
| Smoking | 2 | 2015 | 926 | 0.620 |
Why?
|
| Age Factors | 9 | 2018 | 2872 | 0.610 |
Why?
|
| Dietary Supplements | 4 | 2020 | 453 | 0.610 |
Why?
|
| Infertility, Female | 2 | 2016 | 153 | 0.610 |
Why?
|
| Enclomiphene | 2 | 2016 | 3 | 0.610 |
Why?
|
| Asthenozoospermia | 1 | 2019 | 6 | 0.600 |
Why?
|
| Physicians | 3 | 2024 | 634 | 0.600 |
Why?
|
| Radiation Injuries | 2 | 2014 | 146 | 0.600 |
Why?
|
| Critical Pathways | 2 | 2018 | 74 | 0.600 |
Why?
|
| Cohort Studies | 11 | 2020 | 5123 | 0.580 |
Why?
|
| Penile Diseases | 1 | 2018 | 12 | 0.570 |
Why?
|
| Exosomes | 1 | 2019 | 60 | 0.570 |
Why?
|
| Prostheses and Implants | 2 | 2019 | 148 | 0.570 |
Why?
|
| Biomarkers | 4 | 2024 | 3405 | 0.560 |
Why?
|
| Extracellular Vesicles | 1 | 2019 | 61 | 0.560 |
Why?
|
| Insurance Coverage | 2 | 2016 | 117 | 0.550 |
Why?
|
| Pregnancy Outcome | 4 | 2026 | 630 | 0.550 |
Why?
|
| Fatigue | 2 | 2016 | 199 | 0.550 |
Why?
|
| Doping in Sports | 3 | 2014 | 7 | 0.550 |
Why?
|
| Depression | 2 | 2025 | 1350 | 0.550 |
Why?
|
| Sperm Banks | 4 | 2025 | 8 | 0.550 |
Why?
|
| Clomiphene | 2 | 2016 | 16 | 0.540 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 148 | 0.540 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2017 | 323 | 0.540 |
Why?
|
| Drug Monitoring | 2 | 2020 | 285 | 0.530 |
Why?
|
| Aging | 3 | 2014 | 1264 | 0.530 |
Why?
|
| Aged | 38 | 2025 | 21256 | 0.530 |
Why?
|
| Female | 67 | 2026 | 71181 | 0.530 |
Why?
|
| Ejaculation | 11 | 2003 | 21 | 0.520 |
Why?
|
| Teratozoospermia | 1 | 2017 | 5 | 0.520 |
Why?
|
| Human Growth Hormone | 1 | 2017 | 75 | 0.510 |
Why?
|
| Impotence, Vasculogenic | 2 | 2014 | 7 | 0.510 |
Why?
|
| United States | 21 | 2025 | 11802 | 0.510 |
Why?
|
| Work | 1 | 2016 | 12 | 0.500 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 215 | 0.500 |
Why?
|
| Health Care Costs | 3 | 2016 | 400 | 0.490 |
Why?
|
| Administration, Oral | 3 | 2016 | 709 | 0.490 |
Why?
|
| Men | 1 | 2016 | 7 | 0.490 |
Why?
|
| Injections, Intralesional | 2 | 2024 | 45 | 0.490 |
Why?
|
| Genetic Testing | 5 | 2020 | 1099 | 0.490 |
Why?
|
| Sex Hormone-Binding Globulin | 7 | 2017 | 50 | 0.480 |
Why?
|
| Androstenediol | 1 | 2015 | 1 | 0.470 |
Why?
|
| Sertoli Cells | 18 | 2003 | 76 | 0.470 |
Why?
|
| Androstenedione | 1 | 2015 | 15 | 0.470 |
Why?
|
| Trinucleotide Repeats | 3 | 2013 | 106 | 0.470 |
Why?
|
| Testicular Diseases | 7 | 2016 | 12 | 0.470 |
Why?
|
| Chromosome Aberrations | 5 | 2016 | 577 | 0.470 |
Why?
|
| Dehydroepiandrosterone | 1 | 2015 | 34 | 0.460 |
Why?
|
| Iron | 2 | 2018 | 310 | 0.450 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 5297 | 0.450 |
Why?
|
| Spinal Cord Injuries | 4 | 2016 | 278 | 0.450 |
Why?
|
| Referral and Consultation | 2 | 2018 | 566 | 0.440 |
Why?
|
| Risk Factors | 18 | 2019 | 10959 | 0.440 |
Why?
|
| Body Fluids | 1 | 2015 | 46 | 0.440 |
Why?
|
| Carbolines | 1 | 2014 | 10 | 0.440 |
Why?
|
| Polycythemia | 1 | 2015 | 45 | 0.430 |
Why?
|
| Andropause | 1 | 2014 | 3 | 0.430 |
Why?
|
| Genetic Counseling | 1 | 2016 | 238 | 0.430 |
Why?
|
| Child Mortality | 1 | 2014 | 23 | 0.430 |
Why?
|
| Walking | 1 | 2016 | 234 | 0.420 |
Why?
|
| Sperm-Ovum Interactions | 13 | 1997 | 22 | 0.420 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2014 | 51 | 0.410 |
Why?
|
| Mental Health | 1 | 2017 | 383 | 0.410 |
Why?
|
| Severity of Illness Index | 8 | 2019 | 3101 | 0.410 |
Why?
|
| Young Adult | 13 | 2019 | 10104 | 0.410 |
Why?
|
| Prescription Drugs | 1 | 2014 | 52 | 0.410 |
Why?
|
| Muscle Strength | 1 | 2014 | 82 | 0.410 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 204 | 0.410 |
Why?
|
| Gonadotropins | 2 | 2012 | 31 | 0.400 |
Why?
|
| Educational Status | 1 | 2014 | 281 | 0.400 |
Why?
|
| Organizational Policy | 1 | 2013 | 50 | 0.390 |
Why?
|
| Infant Mortality | 1 | 2014 | 182 | 0.390 |
Why?
|
| Clinical Protocols | 2 | 2013 | 228 | 0.390 |
Why?
|
| Sex Ratio | 1 | 2012 | 12 | 0.380 |
Why?
|
| Mortality | 1 | 2014 | 261 | 0.380 |
Why?
|
| Patients | 1 | 2013 | 122 | 0.370 |
Why?
|
| Vascular Diseases | 1 | 2014 | 155 | 0.370 |
Why?
|
| Fallopian Tubes | 1 | 2013 | 71 | 0.370 |
Why?
|
| Prospective Studies | 16 | 2023 | 6494 | 0.360 |
Why?
|
| Fertilization | 3 | 2025 | 45 | 0.360 |
Why?
|
| Cell Communication | 1 | 2013 | 196 | 0.360 |
Why?
|
| Physical Examination | 5 | 2020 | 169 | 0.360 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 644 | 0.360 |
Why?
|
| Choice Behavior | 1 | 2013 | 132 | 0.360 |
Why?
|
| Nomograms | 1 | 2011 | 38 | 0.350 |
Why?
|
| Emotions | 1 | 2014 | 367 | 0.350 |
Why?
|
| Time Factors | 19 | 2024 | 6279 | 0.350 |
Why?
|
| Paternity | 1 | 2011 | 8 | 0.350 |
Why?
|
| Medical History Taking | 5 | 2020 | 109 | 0.350 |
Why?
|
| Body Composition | 1 | 2014 | 550 | 0.340 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 471 | 0.340 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 310 | 0.340 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 363 | 0.340 |
Why?
|
| Cardiovascular Diseases | 4 | 2017 | 2082 | 0.340 |
Why?
|
| Penile Implantation | 1 | 2011 | 25 | 0.340 |
Why?
|
| Family Planning Services | 2 | 2024 | 39 | 0.330 |
Why?
|
| Sexual Partners | 1 | 2011 | 82 | 0.330 |
Why?
|
| Testicular Neoplasms | 4 | 2019 | 123 | 0.330 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 897 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 1256 | 0.330 |
Why?
|
| Spermatic Cord | 2 | 2009 | 12 | 0.310 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2013 | 903 | 0.310 |
Why?
|
| Specimen Handling | 6 | 2000 | 149 | 0.300 |
Why?
|
| Risk Assessment | 7 | 2017 | 3695 | 0.290 |
Why?
|
| Anthropometry | 1 | 2009 | 190 | 0.290 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2014 | 53 | 0.290 |
Why?
|
| Clinical Trials as Topic | 5 | 2018 | 1139 | 0.290 |
Why?
|
| Demography | 1 | 2009 | 243 | 0.290 |
Why?
|
| Incidence | 9 | 2020 | 3347 | 0.290 |
Why?
|
| Attitude of Health Personnel | 3 | 2020 | 714 | 0.280 |
Why?
|
| Oxidative Stress | 1 | 2013 | 807 | 0.270 |
Why?
|
| Injections, Intramuscular | 2 | 2022 | 187 | 0.270 |
Why?
|
| Decision Making | 1 | 2013 | 684 | 0.270 |
Why?
|
| Risk | 4 | 2019 | 739 | 0.270 |
Why?
|
| Gels | 3 | 2014 | 70 | 0.270 |
Why?
|
| Piperazines | 4 | 2008 | 272 | 0.270 |
Why?
|
| Insulin | 2 | 2012 | 1151 | 0.270 |
Why?
|
| Texas | 5 | 2019 | 3621 | 0.270 |
Why?
|
| Biopsy | 13 | 2025 | 1252 | 0.270 |
Why?
|
| Mutation | 3 | 2014 | 6177 | 0.270 |
Why?
|
| Cross-Sectional Studies | 7 | 2014 | 3834 | 0.260 |
Why?
|
| Societies, Medical | 2 | 2018 | 794 | 0.260 |
Why?
|
| Case-Control Studies | 7 | 2017 | 3454 | 0.260 |
Why?
|
| Egg Yolk | 2 | 2020 | 3 | 0.260 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 998 | 0.250 |
Why?
|
| Sterilization Reversal | 2 | 2018 | 5 | 0.250 |
Why?
|
| Mental Disorders | 1 | 2014 | 904 | 0.250 |
Why?
|
| Drug Implants | 4 | 2013 | 41 | 0.250 |
Why?
|
| History, 20th Century | 3 | 2018 | 366 | 0.240 |
Why?
|
| Health Care Surveys | 2 | 2020 | 282 | 0.240 |
Why?
|
| Receptors, Fc | 1 | 2025 | 29 | 0.240 |
Why?
|
| Epigenesis, Genetic | 2 | 2026 | 749 | 0.240 |
Why?
|
| Critical Illness | 1 | 2010 | 615 | 0.240 |
Why?
|
| Inflation, Economic | 1 | 2025 | 1 | 0.230 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1260 | 0.220 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2007 | 464 | 0.220 |
Why?
|
| Urinary Bladder | 6 | 1998 | 249 | 0.220 |
Why?
|
| Clinical Competence | 3 | 2020 | 1052 | 0.220 |
Why?
|
| Medical Illustration | 1 | 2004 | 18 | 0.210 |
Why?
|
| Chromosomes, Human, Y | 4 | 2014 | 51 | 0.210 |
Why?
|
| Watchful Waiting | 1 | 2025 | 74 | 0.210 |
Why?
|
| Cystatin C | 1 | 2024 | 71 | 0.210 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 20 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 5 | 2014 | 1306 | 0.200 |
Why?
|
| Reproductive Techniques | 5 | 2002 | 7 | 0.200 |
Why?
|
| Cystic Fibrosis | 3 | 2021 | 267 | 0.200 |
Why?
|
| Health Surveys | 4 | 2016 | 263 | 0.200 |
Why?
|
| Tamoxifen | 2 | 2014 | 350 | 0.200 |
Why?
|
| Body Mass Index | 4 | 2024 | 1695 | 0.200 |
Why?
|
| DNA Damage | 2 | 2019 | 527 | 0.200 |
Why?
|
| Aphrodisiacs | 2 | 2020 | 4 | 0.190 |
Why?
|
| Creatinine | 2 | 2024 | 402 | 0.190 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2002 | 6 | 0.190 |
Why?
|
| Suture Techniques | 1 | 2004 | 180 | 0.190 |
Why?
|
| Reference Values | 8 | 2019 | 692 | 0.190 |
Why?
|
| Comprehensive Health Care | 1 | 2002 | 13 | 0.190 |
Why?
|
| Injections | 4 | 2014 | 114 | 0.190 |
Why?
|
| Animals | 38 | 2025 | 34374 | 0.190 |
Why?
|
| Robotic Surgical Procedures | 2 | 2018 | 235 | 0.190 |
Why?
|
| Cancer Survivors | 1 | 2025 | 268 | 0.180 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2013 | 41 | 0.180 |
Why?
|
| Alprostadil | 3 | 2010 | 22 | 0.180 |
Why?
|
| Forecasting | 4 | 2015 | 361 | 0.170 |
Why?
|
| Preoperative Care | 3 | 2014 | 358 | 0.170 |
Why?
|
| Adolescent | 18 | 2018 | 20982 | 0.170 |
Why?
|
| Amyloidosis | 1 | 2002 | 71 | 0.170 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 4 | 1990 | 8 | 0.170 |
Why?
|
| DNA Methylation | 2 | 2020 | 1085 | 0.170 |
Why?
|
| Abnormalities, Multiple | 1 | 2007 | 974 | 0.170 |
Why?
|
| Informed Consent | 2 | 2016 | 343 | 0.170 |
Why?
|
| Ultrasonography | 9 | 1996 | 974 | 0.160 |
Why?
|
| Efficiency | 1 | 2021 | 71 | 0.160 |
Why?
|
| Insemination, Artificial | 3 | 2025 | 11 | 0.160 |
Why?
|
| Spermatic Cord Torsion | 2 | 1998 | 16 | 0.160 |
Why?
|
| Embryo Transfer | 2 | 1999 | 53 | 0.160 |
Why?
|
| Cysts | 4 | 1993 | 93 | 0.160 |
Why?
|
| Multiple Birth Offspring | 1 | 1999 | 6 | 0.160 |
Why?
|
| Professional Practice | 1 | 2020 | 40 | 0.160 |
Why?
|
| Reproductive Control Agents | 1 | 2019 | 2 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2002 | 267 | 0.160 |
Why?
|
| Prolactin | 2 | 2017 | 112 | 0.160 |
Why?
|
| DNA | 4 | 2021 | 1442 | 0.150 |
Why?
|
| Symptom Assessment | 1 | 2020 | 110 | 0.150 |
Why?
|
| Leydig Cell Tumor | 1 | 1999 | 7 | 0.150 |
Why?
|
| Electric Stimulation | 2 | 1992 | 249 | 0.150 |
Why?
|
| Body Image | 1 | 2019 | 39 | 0.150 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 2143 | 0.150 |
Why?
|
| Disease Management | 2 | 2015 | 564 | 0.150 |
Why?
|
| Reproductive Health Services | 1 | 2019 | 24 | 0.150 |
Why?
|
| Needs Assessment | 1 | 2020 | 173 | 0.140 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2018 | 41 | 0.140 |
Why?
|
| Cachexia | 1 | 2018 | 55 | 0.140 |
Why?
|
| Anastomosis, Surgical | 2 | 2009 | 175 | 0.140 |
Why?
|
| Urogenital Neoplasms | 1 | 2018 | 14 | 0.140 |
Why?
|
| Iron Overload | 1 | 2018 | 18 | 0.140 |
Why?
|
| Prevalence | 5 | 2019 | 2694 | 0.140 |
Why?
|
| Prostatitis | 1 | 2018 | 21 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2021 | 493 | 0.140 |
Why?
|
| Chronobiology Disorders | 1 | 2018 | 8 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 2018 | 43 | 0.140 |
Why?
|
| Social Media | 1 | 2020 | 119 | 0.140 |
Why?
|
| North America | 1 | 2018 | 256 | 0.140 |
Why?
|
| Androgen-Binding Protein | 6 | 1986 | 26 | 0.140 |
Why?
|
| Endothelin-1 | 1 | 2017 | 40 | 0.130 |
Why?
|
| Europe | 1 | 2018 | 372 | 0.130 |
Why?
|
| Patient Safety | 2 | 2020 | 444 | 0.130 |
Why?
|
| Estrogens | 1 | 2020 | 436 | 0.130 |
Why?
|
| Diabetes Complications | 1 | 1999 | 199 | 0.130 |
Why?
|
| Recovery of Function | 2 | 2016 | 456 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 97 | 0.130 |
Why?
|
| Medical Audit | 1 | 2017 | 96 | 0.130 |
Why?
|
| Sulfones | 4 | 2008 | 73 | 0.130 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 80 | 0.130 |
Why?
|
| Urologists | 1 | 2016 | 11 | 0.130 |
Why?
|
| Cause of Death | 3 | 2014 | 510 | 0.130 |
Why?
|
| Endoscopy | 1 | 2019 | 282 | 0.130 |
Why?
|
| Cytological Techniques | 1 | 1996 | 18 | 0.130 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 236 | 0.130 |
Why?
|
| Interleukin-17 | 1 | 2017 | 128 | 0.130 |
Why?
|
| Mass Screening | 2 | 2015 | 825 | 0.120 |
Why?
|
| Collagen | 1 | 1998 | 289 | 0.120 |
Why?
|
| Southwestern United States | 2 | 2016 | 45 | 0.120 |
Why?
|
| Linear Models | 3 | 2013 | 695 | 0.120 |
Why?
|
| Graft Survival | 1 | 2018 | 466 | 0.120 |
Why?
|
| Perineum | 2 | 2014 | 49 | 0.120 |
Why?
|
| Research Design | 1 | 2020 | 723 | 0.120 |
Why?
|
| Mothers | 1 | 2019 | 371 | 0.120 |
Why?
|
| Complementary Therapies | 1 | 2016 | 43 | 0.120 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 572 | 0.120 |
Why?
|
| Coitus | 3 | 2019 | 22 | 0.120 |
Why?
|
| Evaluation Studies as Topic | 4 | 2008 | 235 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2017 | 419 | 0.110 |
Why?
|
| Oocytes | 1 | 1997 | 283 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2018 | 543 | 0.110 |
Why?
|
| Comorbidity | 3 | 2018 | 1600 | 0.110 |
Why?
|
| Embryo Loss | 1 | 2015 | 25 | 0.110 |
Why?
|
| Microinjections | 4 | 1999 | 41 | 0.110 |
Why?
|
| Placebos | 2 | 2015 | 227 | 0.110 |
Why?
|
| Laser Therapy | 1 | 1997 | 239 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 643 | 0.110 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 326 | 0.110 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2014 | 1 | 0.110 |
Why?
|
| Iontophoresis | 1 | 2014 | 6 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 455 | 0.110 |
Why?
|
| Prostate | 3 | 2014 | 415 | 0.110 |
Why?
|
| Nicardipine | 1 | 2014 | 16 | 0.110 |
Why?
|
| Verapamil | 1 | 2014 | 48 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 169 | 0.110 |
Why?
|
| Colchicine | 1 | 2014 | 40 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 6922 | 0.110 |
Why?
|
| E2F1 Transcription Factor | 1 | 2014 | 49 | 0.110 |
Why?
|
| Reactive Oxygen Species | 2 | 2015 | 518 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 1405 | 0.110 |
Why?
|
| Postoperative Care | 2 | 2008 | 303 | 0.110 |
Why?
|
| Vitamin E | 1 | 2014 | 63 | 0.110 |
Why?
|
| Autoantibodies | 2 | 1994 | 466 | 0.110 |
Why?
|
| Calcium Channel Blockers | 1 | 2014 | 111 | 0.110 |
Why?
|
| Lithotripsy | 1 | 2014 | 29 | 0.110 |
Why?
|
| Personal Satisfaction | 2 | 2013 | 102 | 0.110 |
Why?
|
| Manometry | 1 | 2014 | 72 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2014 | 272 | 0.110 |
Why?
|
| Carnitine | 1 | 2014 | 70 | 0.100 |
Why?
|
| Registries | 2 | 2013 | 1599 | 0.100 |
Why?
|
| California | 1 | 2014 | 128 | 0.100 |
Why?
|
| Y Chromosome | 4 | 2001 | 47 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2014 | 1235 | 0.100 |
Why?
|
| Lung Transplantation | 1 | 2018 | 350 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 152 | 0.100 |
Why?
|
| Chronic Pain | 1 | 2016 | 159 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2016 | 98 | 0.100 |
Why?
|
| Antibodies | 1 | 1995 | 357 | 0.100 |
Why?
|
| Self Report | 1 | 2016 | 563 | 0.100 |
Why?
|
| Death | 1 | 2014 | 77 | 0.100 |
Why?
|
| Health Status | 3 | 2010 | 387 | 0.100 |
Why?
|
| Affect | 1 | 2014 | 170 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2017 | 781 | 0.100 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 568 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2014 | 190 | 0.100 |
Why?
|
| Drug Costs | 1 | 2013 | 62 | 0.100 |
Why?
|
| Sunlight | 1 | 2013 | 27 | 0.100 |
Why?
|
| Arteries | 1 | 2014 | 210 | 0.100 |
Why?
|
| Melatonin | 1 | 2013 | 30 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2014 | 241 | 0.090 |
Why?
|
| Femoral Nerve | 1 | 1992 | 6 | 0.090 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 30 | 0.090 |
Why?
|
| Haploinsufficiency | 1 | 2014 | 264 | 0.090 |
Why?
|
| Ligation | 2 | 2012 | 137 | 0.090 |
Why?
|
| Administration, Topical | 2 | 2014 | 132 | 0.090 |
Why?
|
| Steroids | 1 | 2013 | 172 | 0.090 |
Why?
|
| Sperm Capacitation | 5 | 1997 | 20 | 0.090 |
Why?
|
| Apoptosis | 5 | 1999 | 1861 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2012 | 955 | 0.090 |
Why?
|
| Anesthesia, Local | 1 | 1992 | 39 | 0.090 |
Why?
|
| Bupivacaine | 1 | 1992 | 29 | 0.090 |
Why?
|
| Patient Selection | 3 | 2004 | 726 | 0.090 |
Why?
|
| Disorders of Sex Development | 1 | 2012 | 71 | 0.090 |
Why?
|
| Laparoscopy | 4 | 2008 | 555 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2015 | 1344 | 0.090 |
Why?
|
| Klinefelter Syndrome | 1 | 2011 | 20 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 1316 | 0.090 |
Why?
|
| Brachytherapy | 1 | 2012 | 80 | 0.090 |
Why?
|
| Heart Transplantation | 1 | 2018 | 832 | 0.090 |
Why?
|
| Chromosome Deletion | 3 | 2013 | 650 | 0.090 |
Why?
|
| Sarcoma, Ewing | 1 | 1992 | 117 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 444 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 1997 | 1356 | 0.090 |
Why?
|
| Hot Temperature | 1 | 1992 | 144 | 0.090 |
Why?
|
| Karyotyping | 2 | 2013 | 314 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1078 | 0.090 |
Why?
|
| Deficiency Diseases | 1 | 2011 | 9 | 0.090 |
Why?
|
| Prenatal Diagnosis | 1 | 2016 | 653 | 0.090 |
Why?
|
| Micromanipulation | 1 | 1991 | 1 | 0.090 |
Why?
|
| Stem Cells | 1 | 2016 | 713 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 128 | 0.090 |
Why?
|
| Hydrocarbons, Halogenated | 2 | 1981 | 5 | 0.080 |
Why?
|
| Genetic Markers | 3 | 2014 | 605 | 0.080 |
Why?
|
| Pseudogenes | 1 | 2011 | 50 | 0.080 |
Why?
|
| Antinematodal Agents | 2 | 1981 | 11 | 0.080 |
Why?
|
| Vitamin D | 1 | 2013 | 194 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2011 | 469 | 0.080 |
Why?
|
| Propane | 2 | 1981 | 28 | 0.080 |
Why?
|
| Sterilization, Tubal | 1 | 2010 | 14 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 442 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1405 | 0.080 |
Why?
|
| Data Collection | 2 | 2011 | 371 | 0.080 |
Why?
|
| Insemination, Artificial, Heterologous | 1 | 1990 | 2 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 276 | 0.080 |
Why?
|
| Sarcoma | 1 | 1992 | 210 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 316 | 0.080 |
Why?
|
| Transition to Adult Care | 1 | 2012 | 134 | 0.080 |
Why?
|
| Models, Biological | 1 | 1995 | 1392 | 0.080 |
Why?
|
| Cricetinae | 10 | 2000 | 367 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3917 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2005 | 3130 | 0.080 |
Why?
|
| Marital Status | 1 | 2009 | 33 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2013 | 334 | 0.080 |
Why?
|
| Motor Activity | 1 | 2013 | 508 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 435 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2018 | 1131 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 132 | 0.080 |
Why?
|
| Brain Death | 1 | 2010 | 74 | 0.080 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1990 | 150 | 0.070 |
Why?
|
| Sex Factors | 2 | 2010 | 1346 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2019 | 8589 | 0.070 |
Why?
|
| Proteins | 2 | 2012 | 1027 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2009 | 244 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 223 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 2009 | 122 | 0.070 |
Why?
|
| Darkness | 1 | 2008 | 25 | 0.070 |
Why?
|
| Urethra | 1 | 2008 | 85 | 0.070 |
Why?
|
| Sus scrofa | 1 | 2008 | 115 | 0.070 |
Why?
|
| Peptides | 2 | 2003 | 835 | 0.070 |
Why?
|
| Carrier Proteins | 3 | 1985 | 1024 | 0.070 |
Why?
|
| Longevity | 1 | 2009 | 176 | 0.070 |
Why?
|
| Algorithms | 1 | 2015 | 1686 | 0.070 |
Why?
|
| Genome, Human | 1 | 2014 | 1332 | 0.070 |
Why?
|
| Cattle | 3 | 2025 | 521 | 0.070 |
Why?
|
| Ethics, Medical | 1 | 2010 | 399 | 0.070 |
Why?
|
| Poly T | 1 | 2007 | 1 | 0.070 |
Why?
|
| Arginine | 2 | 2020 | 344 | 0.060 |
Why?
|
| Sildenafil Citrate | 3 | 2008 | 57 | 0.060 |
Why?
|
| Models, Animal | 1 | 2008 | 460 | 0.060 |
Why?
|
| Purines | 3 | 2008 | 115 | 0.060 |
Why?
|
| Constriction, Pathologic | 3 | 1993 | 228 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 3413 | 0.060 |
Why?
|
| Maternal Age | 2 | 2016 | 137 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2648 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2010 | 557 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 2297 | 0.060 |
Why?
|
| Internet | 2 | 2019 | 422 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2019 | 432 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2862 | 0.060 |
Why?
|
| X Chromosome | 2 | 2001 | 331 | 0.060 |
Why?
|
| Ovum | 4 | 1997 | 15 | 0.060 |
Why?
|
| Spermatocytes | 3 | 1999 | 23 | 0.060 |
Why?
|
| Polypropylenes | 1 | 2005 | 15 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2020 | 1636 | 0.060 |
Why?
|
| Foreign-Body Reaction | 1 | 2005 | 16 | 0.060 |
Why?
|
| Hernia, Inguinal | 1 | 2005 | 42 | 0.060 |
Why?
|
| Surgical Mesh | 1 | 2005 | 65 | 0.050 |
Why?
|
| Critical Care | 1 | 2010 | 680 | 0.050 |
Why?
|
| Intestines | 1 | 2008 | 592 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2024 | 101 | 0.050 |
Why?
|
| Radionuclide Imaging | 3 | 1980 | 120 | 0.050 |
Why?
|
| Rats | 8 | 1997 | 3460 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2024 | 137 | 0.050 |
Why?
|
| Genital Diseases, Male | 4 | 1993 | 13 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2989 | 0.050 |
Why?
|
| Quality Control | 3 | 1995 | 118 | 0.050 |
Why?
|
| Prognosis | 3 | 2004 | 4952 | 0.050 |
Why?
|
| Nurses | 1 | 2004 | 79 | 0.050 |
Why?
|
| Endocrine System Diseases | 1 | 2003 | 43 | 0.050 |
Why?
|
| Disease Progression | 2 | 2025 | 2206 | 0.050 |
Why?
|
| Base Pair Mismatch | 1 | 2003 | 20 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 275 | 0.050 |
Why?
|
| Obesity | 1 | 2014 | 2390 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2008 | 760 | 0.050 |
Why?
|
| Imipramine | 2 | 1973 | 17 | 0.050 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 2 | 2013 | 15 | 0.050 |
Why?
|
| Sex Chromosome Aberrations | 2 | 2013 | 62 | 0.050 |
Why?
|
| Imidazoles | 1 | 2003 | 222 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 232 | 0.050 |
Why?
|
| Transferrin | 5 | 1985 | 45 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1413 | 0.050 |
Why?
|
| Chlorohydrins | 1 | 1981 | 1 | 0.050 |
Why?
|
| Epichlorohydrin | 1 | 1981 | 1 | 0.050 |
Why?
|
| Chemical Industry | 1 | 1981 | 7 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2001 | 59 | 0.040 |
Why?
|
| Ovulation Induction | 2 | 2018 | 41 | 0.040 |
Why?
|
| Glutamine | 1 | 2003 | 202 | 0.040 |
Why?
|
| Sural Nerve | 1 | 2001 | 46 | 0.040 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2001 | 47 | 0.040 |
Why?
|
| Benchmarking | 1 | 2002 | 138 | 0.040 |
Why?
|
| Community Health Services | 1 | 2002 | 92 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2001 | 794 | 0.040 |
Why?
|
| Environmental Exposure | 2 | 1981 | 291 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 1 | 2006 | 539 | 0.040 |
Why?
|
| Pregnancy, Multiple | 1 | 2001 | 44 | 0.040 |
Why?
|
| Regression Analysis | 2 | 1994 | 773 | 0.040 |
Why?
|
| Cyclic AMP | 2 | 1998 | 229 | 0.040 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 1977 | 74 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2002 | 237 | 0.040 |
Why?
|
| Medical Laboratory Personnel | 1 | 2000 | 14 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 1999 | 1958 | 0.040 |
Why?
|
| Hormones | 1 | 2001 | 165 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2020 | 46 | 0.040 |
Why?
|
| Health Policy | 1 | 2002 | 227 | 0.040 |
Why?
|
| DNA Repair | 1 | 2003 | 562 | 0.040 |
Why?
|
| Survivors | 1 | 2002 | 354 | 0.040 |
Why?
|
| Orgasm | 1 | 2019 | 6 | 0.040 |
Why?
|
| Panax | 1 | 2019 | 7 | 0.040 |
Why?
|
| Nondisjunction, Genetic | 1 | 1999 | 18 | 0.040 |
Why?
|
| Video Recording | 1 | 2020 | 208 | 0.040 |
Why?
|
| Centrifugation | 1 | 1998 | 18 | 0.040 |
Why?
|
| Cells, Cultured | 7 | 2014 | 2971 | 0.040 |
Why?
|
| Commerce | 1 | 2019 | 58 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2000 | 300 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 173 | 0.030 |
Why?
|
| Syndrome | 2 | 2016 | 1168 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 1002 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 1997 | 29 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2019 | 234 | 0.030 |
Why?
|
| Plant Extracts | 1 | 2019 | 139 | 0.030 |
Why?
|
| Necrosis | 1 | 1998 | 195 | 0.030 |
Why?
|
| Zygote Intrafallopian Transfer | 1 | 1997 | 1 | 0.030 |
Why?
|
| Medical Laboratory Science | 1 | 1997 | 12 | 0.030 |
Why?
|
| Equipment Design | 2 | 2016 | 555 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1998 | 148 | 0.030 |
Why?
|
| Yohimbine | 1 | 1997 | 14 | 0.030 |
Why?
|
| Methods | 4 | 1990 | 115 | 0.030 |
Why?
|
| DNA Copy Number Variations | 2 | 2014 | 1023 | 0.030 |
Why?
|
| Repressor Proteins | 2 | 1999 | 777 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 263 | 0.030 |
Why?
|
| Lymph | 1 | 1976 | 7 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 204 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 155 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2019 | 362 | 0.030 |
Why?
|
| Child | 6 | 2012 | 26299 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 221 | 0.030 |
Why?
|
| Vincristine | 2 | 1997 | 194 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1911 | 0.030 |
Why?
|
| Sexual Behavior, Animal | 1 | 2016 | 60 | 0.030 |
Why?
|
| Organ Size | 2 | 2010 | 435 | 0.030 |
Why?
|
| Education, Medical | 1 | 2000 | 288 | 0.030 |
Why?
|
| Logistic Models | 3 | 2010 | 1831 | 0.030 |
Why?
|
| Internship and Residency | 2 | 2016 | 1215 | 0.030 |
Why?
|
| Inhalation | 1 | 1995 | 8 | 0.030 |
Why?
|
| Weight Lifting | 1 | 1995 | 3 | 0.030 |
Why?
|
| Gonadotropins, Pituitary | 2 | 1987 | 4 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2016 | 161 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 600 | 0.030 |
Why?
|
| Dacarbazine | 2 | 1992 | 93 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2016 | 1454 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 1610 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 155 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 1810 | 0.030 |
Why?
|
| Dronabinol | 2 | 1986 | 30 | 0.030 |
Why?
|
| Bacteriuria | 2 | 1973 | 82 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 1997 | 315 | 0.030 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 312 | 0.030 |
Why?
|
| Immunologic Tests | 1 | 1994 | 17 | 0.030 |
Why?
|
| In Vitro Techniques | 6 | 1986 | 824 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1997 | 1151 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 236 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1999 | 739 | 0.030 |
Why?
|
| Pituitary Hormones | 1 | 2013 | 4 | 0.030 |
Why?
|
| Doxorubicin | 2 | 1992 | 301 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1997 | 773 | 0.030 |
Why?
|
| Receptors, Adrenergic | 1 | 1973 | 18 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 519 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 613 | 0.030 |
Why?
|
| Glomerulonephritis | 1 | 1974 | 75 | 0.030 |
Why?
|
| Buffers | 2 | 1991 | 29 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 1994 | 200 | 0.020 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 1974 | 89 | 0.020 |
Why?
|
| Receptors, FSH | 2 | 1991 | 20 | 0.020 |
Why?
|
| CpG Islands | 1 | 2014 | 337 | 0.020 |
Why?
|
| Urinary Tract Infections | 2 | 1974 | 328 | 0.020 |
Why?
|
| Hematocrit | 1 | 2013 | 108 | 0.020 |
Why?
|
| Repetitive Sequences, Amino Acid | 2 | 2003 | 18 | 0.020 |
Why?
|
| Quinacrine | 2 | 1992 | 3 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 1982 | 124 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 530 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 1990 | 1626 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1992 | 88 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 832 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 1974 | 279 | 0.020 |
Why?
|
| False Negative Reactions | 2 | 1991 | 88 | 0.020 |
Why?
|
| Rectum | 1 | 1992 | 103 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 314 | 0.020 |
Why?
|
| Lipids | 1 | 2015 | 565 | 0.020 |
Why?
|
| Short Stature Homeobox Protein | 1 | 2011 | 10 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2011 | 134 | 0.020 |
Why?
|
| Nerve Block | 1 | 1992 | 62 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2016 | 726 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1992 | 137 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2012 | 134 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 1217 | 0.020 |
Why?
|
| Pituitary Function Tests | 1 | 1990 | 1 | 0.020 |
Why?
|
| Calcinosis | 1 | 1992 | 187 | 0.020 |
Why?
|
| Seminiferous Tubules | 2 | 1987 | 15 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 741 | 0.020 |
Why?
|
| Blood Specimen Collection | 1 | 1990 | 47 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 124 | 0.020 |
Why?
|
| Global Health | 1 | 1995 | 632 | 0.020 |
Why?
|
| Prostatic Diseases | 1 | 1989 | 14 | 0.020 |
Why?
|
| Body Height | 1 | 2011 | 196 | 0.020 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1990 | 43 | 0.020 |
Why?
|
| Sexuality | 1 | 2009 | 10 | 0.020 |
Why?
|
| Program Development | 1 | 2010 | 185 | 0.020 |
Why?
|
| Rats, Inbred Strains | 3 | 1986 | 199 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 3 | 1986 | 49 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 570 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 1521 | 0.020 |
Why?
|
| Fructose | 1 | 1989 | 61 | 0.020 |
Why?
|
| Spermatids | 2 | 1999 | 26 | 0.020 |
Why?
|
| Cyclic AMP Response Element Modulator | 2 | 1999 | 23 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1990 | 222 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 1745 | 0.020 |
Why?
|
| Preservation, Biological | 2 | 1985 | 10 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 1489 | 0.020 |
Why?
|
| Growth Substances | 1 | 1988 | 102 | 0.020 |
Why?
|
| Self Concept | 1 | 2009 | 163 | 0.020 |
Why?
|
| Sympathomimetics | 1 | 1987 | 12 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1990 | 225 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 1556 | 0.020 |
Why?
|
| Sclerosis | 1 | 1987 | 30 | 0.020 |
Why?
|
| Bicarbonates | 1 | 1987 | 98 | 0.020 |
Why?
|
| Hyperprolactinemia | 1 | 1987 | 23 | 0.020 |
Why?
|
| Radiography | 1 | 1989 | 762 | 0.020 |
Why?
|
| Thyroid Diseases | 1 | 1987 | 29 | 0.020 |
Why?
|
| Sodium Bicarbonate | 1 | 1987 | 55 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1987 | 64 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1617 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1987 | 216 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1986 | 260 | 0.020 |
Why?
|
| Mesocricetus | 2 | 2000 | 69 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1989 | 265 | 0.020 |
Why?
|
| Sodium | 1 | 1987 | 281 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 2357 | 0.010 |
Why?
|
| Functional Laterality | 1 | 1986 | 183 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2005 | 75 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1982 | 314 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1987 | 275 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 4516 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1989 | 444 | 0.010 |
Why?
|
| Vardenafil Dihydrochloride | 1 | 2003 | 1 | 0.010 |
Why?
|
| Technetium | 2 | 1974 | 16 | 0.010 |
Why?
|
| Triazines | 1 | 2003 | 33 | 0.010 |
Why?
|
| Cannabinoids | 1 | 1983 | 32 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1982 | 35 | 0.010 |
Why?
|
| Mice | 2 | 2014 | 18487 | 0.010 |
Why?
|
| Transsexualism | 1 | 1982 | 14 | 0.010 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 1973 | 40 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 40 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 609 | 0.010 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2001 | 26 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1982 | 420 | 0.010 |
Why?
|
| Reoperation | 1 | 2005 | 844 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1984 | 769 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1985 | 403 | 0.010 |
Why?
|
| Singapore | 1 | 2001 | 16 | 0.010 |
Why?
|
| Dogs | 2 | 1973 | 630 | 0.010 |
Why?
|
| Fertility Agents, Female | 1 | 2001 | 7 | 0.010 |
Why?
|
| Licensure | 1 | 2001 | 13 | 0.010 |
Why?
|
| Codon | 1 | 2001 | 95 | 0.010 |
Why?
|
| Flushing | 1 | 2000 | 6 | 0.010 |
Why?
|
| Dizziness | 1 | 2000 | 26 | 0.010 |
Why?
|
| Headache | 1 | 2000 | 110 | 0.010 |
Why?
|
| Dyspepsia | 1 | 2000 | 108 | 0.010 |
Why?
|
| Nose | 1 | 2000 | 112 | 0.010 |
Why?
|
| Vision, Ocular | 1 | 2000 | 127 | 0.010 |
Why?
|
| Autoradiography | 1 | 1999 | 65 | 0.010 |
Why?
|
| Exons | 1 | 2001 | 769 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1978 | 37 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1999 | 67 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1999 | 122 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2002 | 502 | 0.010 |
Why?
|
| Geography | 1 | 1998 | 119 | 0.010 |
Why?
|
| Body Weight | 1 | 1982 | 990 | 0.010 |
Why?
|
| Norepinephrine | 2 | 1980 | 156 | 0.010 |
Why?
|
| Histocytological Preparation Techniques | 1 | 1997 | 5 | 0.010 |
Why?
|
| Kinetics | 3 | 1985 | 1101 | 0.010 |
Why?
|
| Vinblastine | 1 | 1997 | 55 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1977 | 2 | 0.010 |
Why?
|
| Meiosis | 1 | 1998 | 112 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1998 | 237 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1977 | 50 | 0.010 |
Why?
|
| Cytosol | 1 | 1977 | 140 | 0.010 |
Why?
|
| Prednisone | 1 | 1997 | 244 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 1999 | 450 | 0.010 |
Why?
|
| Cell Count | 1 | 1977 | 217 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1976 | 157 | 0.010 |
Why?
|
| Atrophy | 1 | 1977 | 251 | 0.010 |
Why?
|
| Muscle Contraction | 2 | 1980 | 154 | 0.010 |
Why?
|
| Bucladesine | 2 | 1986 | 18 | 0.010 |
Why?
|
| Plastics | 1 | 1995 | 14 | 0.010 |
Why?
|
| Child, Preschool | 3 | 1977 | 15057 | 0.010 |
Why?
|
| Iodohippuric Acid | 1 | 1974 | 2 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1976 | 670 | 0.010 |
Why?
|
| Craniopharyngioma | 1 | 1994 | 34 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1974 | 74 | 0.010 |
Why?
|
| Hyalin | 1 | 1974 | 6 | 0.010 |
Why?
|
| Rabbits | 1 | 1995 | 633 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1974 | 70 | 0.010 |
Why?
|
| Uremia | 1 | 1974 | 37 | 0.010 |
Why?
|
| Mestranol | 1 | 1973 | 2 | 0.010 |
Why?
|
| Ethynodiol Diacetate | 1 | 1973 | 2 | 0.010 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1994 | 68 | 0.010 |
Why?
|
| Phentolamine | 1 | 1973 | 16 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1973 | 9 | 0.010 |
Why?
|
| Fibrin | 1 | 1974 | 64 | 0.010 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1974 | 66 | 0.010 |
Why?
|
| Parasympathetic Nervous System | 1 | 1973 | 14 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 1974 | 80 | 0.010 |
Why?
|
| Transducers | 1 | 1973 | 22 | 0.010 |
Why?
|
| Pituitary Neoplasms | 1 | 1994 | 78 | 0.010 |
Why?
|
| Atropine | 1 | 1973 | 30 | 0.010 |
Why?
|
| Proteinuria | 1 | 1974 | 106 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 1973 | 40 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 1973 | 55 | 0.010 |
Why?
|
| Protein Binding | 1 | 1977 | 1712 | 0.010 |
Why?
|
| Stimulation, Chemical | 2 | 1986 | 43 | 0.010 |
Why?
|
| Electromyography | 1 | 1973 | 141 | 0.010 |
Why?
|
| Sulfur | 1 | 1972 | 11 | 0.010 |
Why?
|
| Colloids | 1 | 1972 | 16 | 0.010 |
Why?
|
| Urination | 1 | 1972 | 27 | 0.010 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 2 | 1984 | 13 | 0.010 |
Why?
|
| Cell Nucleus | 2 | 1985 | 567 | 0.010 |
Why?
|
| Cystitis | 1 | 1972 | 48 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1974 | 389 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1992 | 172 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1991 | 25 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1991 | 99 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1992 | 312 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1974 | 1234 | 0.000 |
Why?
|
| Sepsis | 1 | 1974 | 501 | 0.000 |
Why?
|
| Acute Disease | 1 | 1992 | 1153 | 0.000 |
Why?
|
| Metaphase | 1 | 1988 | 31 | 0.000 |
Why?
|
| Sex Preselection | 1 | 1988 | 6 | 0.000 |
Why?
|
| Mitogens | 1 | 1988 | 30 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1998 | 4696 | 0.000 |
Why?
|
| Blood | 1 | 1988 | 100 | 0.000 |
Why?
|
| Culture Media | 1 | 1988 | 175 | 0.000 |
Why?
|
| Cisplatin | 1 | 1989 | 286 | 0.000 |
Why?
|
| Kidney | 1 | 1974 | 1309 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1988 | 334 | 0.000 |
Why?
|
| Fluorescent Dyes | 1 | 1988 | 251 | 0.000 |
Why?
|
| Cell Division | 1 | 1988 | 731 | 0.000 |
Why?
|
| Plasminogen Activators | 1 | 1986 | 19 | 0.000 |
Why?
|
| Lung | 1 | 1974 | 1565 | 0.000 |
Why?
|
| Intradermal Tests | 1 | 1985 | 3 | 0.000 |
Why?
|
| Histamine | 1 | 1985 | 52 | 0.000 |
Why?
|
| Hydroxyapatites | 1 | 1985 | 2 | 0.000 |
Why?
|
| Adsorption | 1 | 1985 | 34 | 0.000 |
Why?
|
| Diabetic Neuropathies | 1 | 1985 | 56 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1994 | 1298 | 0.000 |
Why?
|
| Cold Temperature | 1 | 1985 | 81 | 0.000 |
Why?
|
| Filtration | 1 | 1985 | 20 | 0.000 |
Why?
|
| Ethanolamines | 1 | 1985 | 24 | 0.000 |
Why?
|
| Heterochromatin | 1 | 1985 | 45 | 0.000 |
Why?
|
| Zona Pellucida | 1 | 1984 | 11 | 0.000 |
Why?
|
| RNA, Ribosomal | 1 | 1985 | 52 | 0.000 |
Why?
|
| Inhibins | 1 | 1985 | 85 | 0.000 |
Why?
|
| Cannabinol | 1 | 1983 | 1 | 0.000 |
Why?
|
| Transglutaminases | 1 | 1983 | 27 | 0.000 |
Why?
|
| Cannabidiol | 1 | 1983 | 19 | 0.000 |
Why?
|
| Acyltransferases | 1 | 1983 | 62 | 0.000 |
Why?
|
| Cell Line | 1 | 1988 | 2605 | 0.000 |
Why?
|
| Cell Survival | 1 | 1985 | 854 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1985 | 432 | 0.000 |
Why?
|
| Adrenergic Fibers | 1 | 1980 | 3 | 0.000 |
Why?
|
| Cholinergic Fibers | 1 | 1980 | 9 | 0.000 |
Why?
|
| Acetylcholinesterase | 1 | 1980 | 15 | 0.000 |
Why?
|
| Acetylcholine | 1 | 1980 | 82 | 0.000 |
Why?
|
| Doppler Effect | 1 | 1979 | 2 | 0.000 |
Why?
|
| Prostaglandins A | 1 | 1978 | 1 | 0.000 |
Why?
|
| Prostaglandins E | 1 | 1978 | 8 | 0.000 |
Why?
|
| Prostaglandins F | 1 | 1978 | 9 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1985 | 2568 | 0.000 |
Why?
|
| Sperm Agglutination | 1 | 1978 | 3 | 0.000 |
Why?
|
| Viscosity | 1 | 1978 | 39 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1978 | 239 | 0.000 |
Why?
|
| Sheep | 1 | 1978 | 225 | 0.000 |
Why?
|
| Sperm Maturation | 1 | 1978 | 15 | 0.000 |
Why?
|
| Ultrasonics | 1 | 1977 | 31 | 0.000 |
Why?
|
| Veins | 1 | 1977 | 99 | 0.000 |
Why?
|
| Pennsylvania | 1 | 1973 | 62 | 0.000 |
Why?
|
| Intrauterine Devices | 1 | 1973 | 14 | 0.000 |
Why?
|
| Klebsiella Infections | 1 | 1973 | 63 | 0.000 |
Why?
|
| Urinary Tract | 1 | 1973 | 61 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1973 | 277 | 0.000 |
Why?
|
| Escherichia coli Infections | 1 | 1973 | 198 | 0.000 |
Why?
|